Traumatic Brain Injury Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the TBI, historical and forecasted epidemiology and the TBI market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Traumatic Brain Injury Market Size @ Traumatic Brain Injury Market Outlook- https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Traumatic Brain Injury Market Report
• In May 2025, Hope Biosciences announced a study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury.
• In May 2025, Merz Pharmaceuticals GmbH conducted a study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.
• In May 2025, Ipsen announced a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
• In the 7MM, the US accounted for the highest number of incident cases of TBI, with nearly 3,042,000 cases in 2024.
• Among EU4 and the UK, the maximum cases were reported in Germany followed by France, and the least cases were found in Spain.
• In the UK, approximately 125,000 adults and 49,000 children experienced TBI in 2024.
• Japan accounted for about 280,000 cases of mild TBI, 43,000 cases of moderate TBI and about 5,900 cases of severe TBI, in 2024.
• In the 7MM, males emerged as the most affected group by TBI in 2024, outpacing females in incidence and impact.
• The leading Traumatic Brain Injury Companies such as Oxeia Biopharmaceuticals, Hope Biosciences, Oragenics, Cellvation, SHINKEI Therapeutics, BioVie, Beyond Barriers Therapeutics, AivoCode, Abliva/Owl Therapeutics, Neuroplast and others.
• Promising Traumatic Brain Injury Pipeline Therapies such as Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, HB-adMSCs, Rivastigmine, Dexanabinol and others.

Stay ahead in the Traumatic Brain Injury Treatment Market Size with DelveInsight's Strategic Report @ Traumatic Brain Injury Therapeutics Market Report- https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Traumatic Brain Injury Epidemiology Segmentation in the 7MM
• Total Traumatic Brain Injury Incident Cases
• Traumatic Brain Injury Severity-specific Distribution of Incident Cases
• Traumatic Brain Injury Gender-specific Distribution of Incident Cases
• Traumatic Brain Injury Age-specific Distribution of Incident Cases

Download the report to understand which factors are driving Traumatic Brain Injury Epidemiology trends @ Traumatic Brain Injury Prevalence- https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Traumatic Brain Injury Marketed Drugs
• AKUUGO (Vandefitemcel): SanBio
AKUUGO suspension for intracranial implantation is a human (allogeneic) bone marrow-derived modified mesenchymal stem cell that is produced by modifying and culturing mesenchymal stem cells derived from the bone marrow aspirate of healthy adults. It was approved in July 2024, under the Sakigake Designation Program, and obtained conditional and time-limited marketing approval for the human somatic stem cell-processed product 'AKUUGO suspension for intracranial implantation' in Japan for the indication of improving chronic motor paralysis resulting from TBI.

Traumatic Brain Injury Emerging Drugs
• OXE103: Oxeia Biopharmaceuticals
OXE103 is synthetic human ghrelin, an endogenous hormone. OXE103 freely crosses the blood-brain barrier and helps stabilize metabolic and energy brain dysfunction following a concussion. OXE103 uniquely targets the hippocampus region of the brain, an area important for cognition and memory. In February 2025, the company announced that it is planning to initiate the Phase IIb trials for OXE103 later in 2025.

• ONP-002: Oragenics
ONP-002 is a first-in-class enantiomeric-neurosteroid being developed for the treatment of mTBI (concussion). The Intellectual Property (IP) encompasses the structure, synthetic preparation, and methods of use for the drug, which has demonstrated positive preclinical molecular and behavioral effects within hours in animal and cell culture models of neuronal injury. In March 2025, Oragenics announced the submission of its IB application in preparation for its Phase II clinical trial using ONP-002 in Australia. This milestone represents an important step in advancing ONP-002, a novel intranasal neurosteroid, as a potential treatment for mTBI, and initiate proof of concept Phase IIb in the US with an open IND approved by the FDA.

To learn more about Traumatic Brain Injury treatment guidelines, visit @ Traumatic Brain Injury Treatment Market Landscape- https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Traumatic Brain Injury Companies
Oxeia Biopharmaceuticals, Hope Biosciences, Oragenics, Cellvation, SHINKEI Therapeutics, BioVie, Beyond Barriers Therapeutics, AivoCode, Abliva/Owl Therapeutics, Neuroplast and others.

Traumatic Brain Injury Market Outlook
Traumatic Brain Injury is a complex condition caused by an external impact to the head, leading to brain damage. Managing TBI is challenging yet essential, requiring medical intervention, rehabilitation, and symptom management. Treatment approaches range from cognitive therapy to radical surgeries like bilateral decompressive craniotomies. While guidelines exist, they must be adapted to individual cases due to healthcare constraints. Currently, no FDA-approved therapies for TBI exist, and only off-label medications are used to manage its symptoms. Available treatments include psychostimulants, antidepressants, anticonvulsants, beta-blockers, and pain relievers, addressing neuropsychiatric, neurocognitive, and motor complications. Advances in acute care have led to a growing population of TBI survivors, many with long-term disabilities, highlighting the urgent need for approved treatment options.

Learn more about the FDA-approved drugs for Traumatic Brain Injury @ Drugs for Traumatic Brain Injury Treatment- https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Traumatic Brain Injury Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Traumatic Brain Injury Companies- Oxeia Biopharmaceuticals, Hope Biosciences, Oragenics, Cellvation, SHINKEI Therapeutics, BioVie, Beyond Barriers Therapeutics, AivoCode, Abliva/Owl Therapeutics, Neuroplast and others.
• Traumatic Brain Injury Pipeline Therapies- Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, HB-adMSCs, Rivastigmine, Dexanabinol and others.
• Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury Market Drivers and Barriers
• Traumatic Brain Injury Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Traumatic Brain Injury Drugs in development @ Traumatic Brain Injury Clinical Trials Assessment- https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Report Introduction
3. Traumatic Brain Injury (TBI) Market Overview by Therapy
4. Epidemiology and Market Methodology of TBI
5. Executive Summary of TBI
6. Key Events
7. Traumatic Brain Injury Market Disease Background and Overview
8. Traumatic Brain Injury Epidemiology and Patient Population
9. Traumatic Brain Injury Patient Journey
10. Traumatic Brain Injury Marketed Therapies
11. Traumatic Brain Injury Emerging Therapies
12. Traumatic Brain Injury: 7MM
13. Traumatic Brain Injury Unmet Needs
14. Traumatic Brain Injury SWOT Analysis
15. Traumatic Brain Injury KOL Views
16. Traumatic Brain Injury Market Access and Reimbursement
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer

List of Top Selling Market Research Reports in 2025

CAR-T Pipeline- https://www.delveinsight.com/report-store/car-t-pipeline-insight
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Ly3454738 Drug Insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Periodontal Disease Market- https://www.delveinsight.com/report-store/periodontal-disease-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-pipeline-insight
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Lice Infestations Market- https://www.delveinsight.com/report-store/lice-infestations-pipeline-insight
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market-insight
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.